- Home
- SYBX vs LGVN Comparison
SYBX vs LGVN Comparison
Compare SYBX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- LGVN
- Stock Information
- Founded
- SYBX N/A
- LGVN 2014
- Country
- SYBX United States
- LGVN United States
- Employees
- SYBX N/A
- LGVN N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- SYBX Health Care
- LGVN Health Care
- Exchange
- SYBX Nasdaq
- LGVN Nasdaq
- Market Cap
- SYBX 16.4M
- LGVN 16.4M
- IPO Year
- SYBX N/A
- LGVN 2021
- Fundamental
- Price
- SYBX $1.71
- LGVN $0.75
- Analyst Decision
- SYBX
- LGVN Strong Buy
- Analyst Count
- SYBX 0
- LGVN 2
- Target Price
- SYBX N/A
- LGVN $6.50
- AVG Volume (30 Days)
- SYBX 21.1K
- LGVN 416.4K
- Earning Date
- SYBX 11-11-2025
- LGVN 11-11-2025
- Dividend Yield
- SYBX N/A
- LGVN N/A
- EPS Growth
- SYBX N/A
- LGVN N/A
- EPS
- SYBX N/A
- LGVN N/A
- Revenue
- SYBX N/A
- LGVN $2,073,000.00
- Revenue This Year
- SYBX N/A
- LGVN N/A
- Revenue Next Year
- SYBX N/A
- LGVN N/A
- P/E Ratio
- SYBX N/A
- LGVN N/A
- Revenue Growth
- SYBX N/A
- LGVN 68.67
- 52 Week Low
- SYBX $0.90
- LGVN $0.63
- 52 Week High
- SYBX $1.96
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- SYBX 69.98
- LGVN 35.53
- Support Level
- SYBX $1.45
- LGVN $0.74
- Resistance Level
- SYBX $1.77
- LGVN $0.85
- Average True Range (ATR)
- SYBX 0.07
- LGVN 0.05
- MACD
- SYBX 0.03
- LGVN 0.02
- Stochastic Oscillator
- SYBX 83.33
- LGVN 21.23
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.